Blockchain Registration Transaction Record

Scinai Immunotherapeutics Receives Positive Regulatory Feedback for Plaque Psoriasis Clinical Trial

Scinai Immunotherapeutics receives positive regulatory feedback for its plaque psoriasis clinical trial, showing potential advancements in the development of a treatment for patients with mild to moderate plaque psoriasis.

This news matters as it shows the progress of a biotechnology company in the development of a potential treatment for plaque psoriasis, a condition with a large unmet medical need. The positive regulatory feedback from the European equivalent to a pre-IND meeting with the U.S. FDA reflects potential advancements in the development of this product, which could significantly impact patients with mild to moderate plaque psoriasis.